← Back to Search

MEK inhibitor

MEK162, MEK inhibitor; oral for Ovarian Cancer

Phase 3
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization until disease progression or death (up to 24 months)
Awards & highlights

Study Summary

This study is evaluating whether a drug called MEK162 can be used to treat ovarian cancer.

Eligible Conditions
  • Ovarian Cancer
  • Serous Carcinoma of the Fallopian Tube
  • Serous Carcinoma of the Peritoneum

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization until disease progression or death (up to 24 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization until disease progression or death (up to 24 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Secondary outcome measures
Disease Control Rate (DCR)
Duration of Response (DOR)
Maximum Observed Plasma Concentration (Cmax) of MEK162
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MEK162Experimental Treatment1 Intervention
Group II: Physician's choice chemotherapyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEK162, MEK inhibitor; oral
2012
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,570 Previous Clinical Trials
10,910,099 Total Patients Enrolled
21 Trials studying Ovarian Cancer
2,786 Patients Enrolled for Ovarian Cancer
Pfizer Pfizer CT.gov Call CenterStudy DirectorPfizer
22 Previous Clinical Trials
6,266 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
2013. "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01849874.
~29 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top